Stock Analiz

Nuwellis, Inc. NUWE

Biotechnology: Electromedical & Electrotherapeutic Apparatus · data as of November 13, 2026

$4.90Market cap $3M
Open the interactive analysis →

Nuwellis, Inc. (NUWE) is a healthcare company listed in the US with a market value of about $3M. In the twelve months to September 30, 2026 it had revenue of $9M and net income of -$14M, a net margin of -152.8%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 2% a year, a 5-year average ROIC of -190%.

About Nuwellis

Nuwellis is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus. Revenue went from $295000 in 2014 to $8M in 2025, growth of about 35.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 583473% over three years (dilution for shareholders). It spends 33% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.3
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-464.3%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-5.4%
Revenue growth (5 yrs, per year)2.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-196.9%
ROIC (5-yr avg.)-190.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$9M$8M$9M$9M$9M$8M$7M$6M$5M$4M$1M
Net income-$14M-$18M-$11M-$20M-$15M-$20M-$16M-$18M-$17M-$13M-$16M
Free cash flow-$12M-$11M-$10M-$18M-$15M-$18M-$17M-$17M-$15M-$12M-$16M
EPS (diluted)$-19.94$-25.39$-353.30$-15122.63$-122819.18$-419481.51$-1557587.33$-40713318.28$-184773466.86$-2302038866.54$-32567730308.69
Net margin-152.8%-211.9%-127.8%-228.0%-170.0%-246.9%-212.8%-328.7%-340.8%-376.6%-1225.1%
ROIC—-299.3%-122.7%-371.4%-101.9%-57.0%-81.1%-586.9%-226.7%-72.1%-888.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Nuwellis pay a dividend?

Not currently.

Is Nuwellis a good stock to buy?

We do not give buy or sell advice. Nuwellis scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.